Michael Gelband’s Adverum Biotechnologies ADVM Stock Holding History

Michael Gelband’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24,612	Closed	-$173K	–	1454
2024 Q3	$173K	Buy	+24,612	New	+$179K	﹤0.01%	1470
2022 Q2	–	Sell	-39,636	Closed	-$519K	–	1888
2022 Q1	$519K	Buy	39,636 +7,856	+25%	+$115K	0.01%	1487
2021 Q4	$559K	Sell	31,780 -16,486	-34%	-$330K	0.01%	1340
2021 Q3	$1.05M	Buy	48,266 +44,560	+1,202%	+$1.14M	0.01%	1001
2021 Q2	$130K	Buy	+3,706	New	+$200K	﹤0.01%	2094
2021 Q1	–	Sell	-1,211	Closed	-$131K	–	2076
2020 Q4	$131K	Buy	+1,211	New	+$150K	﹤0.01%	1800
2020 Q3	–	Sell	-1,038	Closed	-$217K	–	1697
2020 Q2	$217K	Buy	+1,038	New	+$184K	0.01%	1477

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Michael Gelband's ADVM Position: Q4 2024 in Review

Michael Gelband sold out of Adverum Biotechnologies (ADVM) in Q4 2024, closing a stake of 24,612 shares — an estimated $173K sold.

Michael Gelband first reported a position in ADVM in Q2 2020 and held it in 7 quarters. The position peaked at $1.05M in Q3 2021. 69 funds tracked by Wall St. Rank hold ADVM as of Q4 2024.

Michael Gelband reported no remaining Adverum Biotechnologies position as of Q4 2024 after selling out during the quarter.
Michael Gelband sold 24,612 Adverum Biotechnologies shares in Q4 2024, an estimated $173K.
Michael Gelband first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 7 quarters.
Michael Gelband's Adverum Biotechnologies position peaked at $1.05M in Q3 2021.
69 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.